In the rapidly evolving biotech landscape, India-based Avammune Therapeutics is emerging as a transformative force in cancer and autoimmune treatment—without making loud headlines. Recently, the startup raised $12 million in Series A funding, co-led by Capital 2B, Shastra VC, and Kotak Alternate Asset Managers’ Life Sciences Fund I, with backing from IvyCap Ventures and 1Crowd.
Founded in 2020 by Arun B Papaiah, Srinivasan Namala, and Aditya Kulkarni, Avammune focuses on small molecule therapies that fine-tune the immune system to target diseases more precisely. Its lead candidate, AVA-NP-695, is an ENPP1 inhibitor showing significant anti-tumor activity in preclinical models of osteosarcoma, Ewing’s sarcoma, and breast cancer.
What sets Avammune apart is its dual focus on scientific innovation and clinical viability. With its newly raised capital, the company plans to expand its IP portfolio and push AVA-NP-695 into clinical development, while also progressing other pipeline candidates.
In a space often dominated by global giants, Avammune is quietly building a foundation that could redefine how immune modulation is used to treat complex diseases. Their work may soon put them at the forefront of the next wave of precision medicine.